Colorectal Cancer
Conditions
Keywords
elderly patients, advanced colorectal cancer, chemotherapy, S-1, 5-fluorouracil, leucovorin
Brief summary
This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.
Detailed description
This is a randomized phase Ⅱ study, in which S-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in elderly patients in the first-line setting. The other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.
Interventions
DRUGS-1, Leucovorin
S-1 : The initial dosage of S-1 is determined by the body surface area: Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day Leucovorin: 25mg twice per day po. The treatment is given for one week,and no chemotherapy is given for the following one week.
leucovorin: 400mg/m2 intravenous infusion d1; 5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours repeat every 2 weeks
Sponsors
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent * Oral medication is acceptable * Histologically confirmed colorectal carcinoma * Male or female ≥ 65 years of age * No prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant chemotherapy with an interval of ≥ 180 days) * Presence of at least one target lesion measurable by CT scan or MRI,within 15 days prior to trial * The lab values within 2 weeks prior to trial should meet: PLT ≥7.5\*10\^4/mm3 ANC≥2000/mm3 HB≥100g/L Total bilirubin \< upper limit of normal level ALT/AST/ALP \< 2.5 x UNL (\<5 x UNL for patients with liver or bone metastasis) Serum creatinine \< UNL * Performance status (ECOG) 0\ 1 * Life expectation longer than 90 days
Exclusion criteria
* Allergy to S-1,fluorouracil or leucovorin * Any investigational agent(s) within 4 weeks prior to entry * Previous or currently exposure to certain drugs which are proved to have influence on blood drug concentration * Active infection * Severe organ failures or diseases, including: intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease, cardiovascular disorder or myocardial infarction,renal or liver failure, severe psychiatric illness,cerebral vascular disease and sever GI ulcer which need blood infusion. * Uncontrolled hydrothorax,ascites and hydropericardium * Multiple bone metastatic lesions * Brain metastases * Chronic diarrhea or digestive disfunction * Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment) * Strong willingness to receive surgery or highly potential to have intestinal obstruction which may need surgery intervention * Other conditions that primary investigate or investigator consider to be unsuitable for the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | six weeks |
Secondary
| Measure | Time frame |
|---|---|
| disease control rate | six weeks |
| time to treatment failure | six weeks |
| progression free survival | six weeks |
| quality of life | six weeks |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | six weeks |
| overall survival | three months |
Countries
China
Contacts
Primary ContactJin Li, MD,PhD
Backup ContactWenhua Li, MS
Outcome results
None listed